NIA Small Business Showcase: NeuroScope Inc.

Image

The majority of Alzheimer’s disease patients suffer from neurovascular deficits, which has important implications for disease monitoring and treatment planning. Neurovascular pathologies negatively affect the clearance of protein aggregations and metabolic waste from the brain; if exacerbated, those pathologies increase the likelihood of cerebral bleeding or stroke. Currently, there is no established diagnosis and monitoring tool to assess brain neurovascular and clearance system health. The limited options available require neuroradiologic visual scoring, which is both extremely time-consuming and unreliable. These limitations hinder the ability to assess neurovascular health for diagnosis or assess the therapeutics’ efficacy.

NeuroScope Inc. has developed fully automated quantitative tools using magnetic resonance imaging (MRI) to assess neurovascular health and brain clearance systems reliably and efficiently. These tools are available via our business-to-business (B2B) cloud-based service. Our solution enables (1) improved patient enrollment, enrichment, and subtyping in clinical trial settings and (2) cost-efficient diagnostics aid for neuroradiologists.

The main consumers of NeuroScope’s technologies are the neuroradiology sector and pharmaceutical industry, and the company will provide cost-efficient precision medicine imaging markers to pharmaceutical companies and neuroradiology departments. The Global Alzheimer’s Disease Diagnostic Market is expected to reach $18.76 billion by 2028. On the clinical cognitive impairment and dementia diagnosis spectrum, vascular dementia accounts for roughly 20% of all dementia, or a $3.75 billion share of the market. NeuroScope has no known competitor at present and upon U.S. Food and Drug Administration (FDA) approval will initially target 40% of the U.S. market.

Current clinical neuroradiology workflows for assessing the brain clearance system are manual and extremely time-consuming. This has a severe impact on turnaround times for radiology reports. Using NeuroScope’s fully automated cloud-based service reduces turnaround time from hours to a few minutes, with proven superior accuracy.